Inicio・Lista de Acciones・Genmab A-S
Search

Genmab A-S

Cerrado

2,103 4.01

Neutral

Precios actualizados 17 ago 2026, 14:54 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

2007

Máximo

2030

Métricas clave

By Trading Economics

Ingresos

243M

295M

Ventas

259M

1.2B

P/B

Media del Sector

24.245

57.002

BPA

34.85

Margen de beneficios

25.541

Empleados

3,119

EBITDA

216M

431M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-1.49% downside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

11B

124B

Apertura anterior

2098.99

Cierre anterior

2103

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 ago 2026, 23:51 UTC

U.S. Industrial Production MoM data set for August 18, 2026, amid mixed economic signals and a forecasted increase of only 0.3%.

Leer

15 ago 2026, 23:51 UTC

Bitcoin is trading roughly flat during Saturday's session, remaining near the lower end of its one-month trading range and below its 20-day moving average.

Leer

15 ago 2026, 23:41 UTC

U.S. equities pull back amid disappointing retail sales and consumer sentiment, while geopolitical tensions and upcoming FOMC Minutes raise concerns for market stability.

Leer

15 ago 2026, 23:41 UTC

European equity and bond markets closed for holiday as U.S. consumer sentiment drops, raising concerns over economic stability ahead of key data releases.

Leer

15 ago 2026, 23:41 UTC

French, Italian, and Spanish markets closed for holiday as U.S. consumer sentiment drops sharply, raising concerns over inflation and potential Federal Reserve rate hikes.

Leer

15 ago 2026, 23:41 UTC

Market Complacency Amidst Bond Volatility: U.S. Stocks Slip as Consumer Sentiment Falls and Retail Sales Decline, While Crypto Shows Resilience.

Leer

15 ago 2026, 23:41 UTC

Cautious Optimism for Stabilization in Canadian Housing Prices Ahead of August 20 Index Release Amid Mixed Economic Signals.

Leer

15 ago 2026, 23:41 UTC

Market Analysts Brace for Philadelphia Fed Manufacturing Index Release Amid Disappointing Retail Sales and Economic Uncertainty.

Leer

15 ago 2026, 23:31 UTC

China's House Price Index YoY release on August 17, 2026, shows cautious optimism as home price declines ease amid mixed economic sentiment and global investor confidence.

Leer

15 ago 2026, 23:11 UTC

Cautious Market Sentiment Ahead of July 2026 Building Permits Data Release, Forecasting 1.37 Million Issued Amid Recent Volatility

Leer

15 ago 2026, 23:11 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious market sentiment and global economic uncertainties.

Leer

15 ago 2026, 23:01 UTC

Upcoming Housing Starts Data Release on August 18, 2026, Amid Concerns Over Consumer Spending and Inflation Impacting Real Estate Markets.

Leer

15 ago 2026, 23:01 UTC

U.S. Import Prices Expected to Rise 0.1% Amid Positive Inflation Sentiment and Reduced Fed Rate Hike Expectations

Leer

15 ago 2026, 23:01 UTC

U.S. Export Prices Expected to Drop 0.2% Amid Slowing Inflation and Weak Retail Sales, Influencing Fed's Interest Rate Decisions

Leer

15 ago 2026, 23:01 UTC

Market Awaits U.S. Building Permits Data Amid Optimism for Construction Growth and Infrastructure Investments.

Leer

15 ago 2026, 23:01 UTC

U.S. Housing Starts Data for July 2026 Set to Release on August 18, Amid Mixed Market Sentiment and Forecast of 1.35 Million Units

Leer

15 ago 2026, 23:01 UTC

EUR/CAD is trading roughly flat during after-market hours, showing little change since Friday's close and remaining near the lower end of its one-month range.

Leer

15 ago 2026, 22:51 UTC

Australia's Westpac Consumer Confidence Index set for August 18, 2026 release amid global economic uncertainties and mixed market performance.

Leer

15 ago 2026, 22:51 UTC

Canada's July 2026 Housing Starts Data Release Expected at 248K Amid Cautious Market Sentiment and Volatile Trends.

Leer

15 ago 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% YoY Amid Global Economic Pressures and Potential BoJ Interest Rate Hike

Leer

15 ago 2026, 22:51 UTC

Japan's July Exports YoY Data Set for Release Amid Optimistic Market Sentiment and Strong Nikkei Performance.

Leer

15 ago 2026, 22:51 UTC

Japan's July trade balance expected to show a -680 billion yen deficit amid rising import costs and weak yen, while equities gain on Wall Street optimism.

Leer

15 ago 2026, 22:51 UTC

Japan's Inflation Rate Release on August 20 Expected to Impact Monetary Policy and Market Sentiment Amid Anticipated Interest Rate Hikes.

Leer

15 ago 2026, 22:41 UTC

NY Empire State Manufacturing Index Set for Release Amid Caution Over Disappointing Retail Sales and Economic Sentiment.

Leer

15 ago 2026, 22:41 UTC

Canada's Inflation Rate Expected to Rise 0.5% in July Amid Mixed Market Sentiments and External Economic Pressures

Leer

15 ago 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Release on August 19 Expected to Impact Housing Market Amid Cooling Inflation and Interest Rates

Leer

15 ago 2026, 22:41 UTC

Canada's July Inflation Rate Expected to Rise from 2.8% to 3%, Amid Geopolitical Tensions and Supply Chain Disruptions

Leer

15 ago 2026, 22:41 UTC

Canada's Core Inflation Rate Release on August 17, 2026, Sparks Caution Among Investors Amid Geopolitical Tensions and Trade Uncertainty.

Leer

15 ago 2026, 22:41 UTC

Avalanche is trading lower today, with no specific news identified. The asset remains within its one-month range amid shifting investment patterns among younger investors.

Leer

15 ago 2026, 22:32 UTC

Japan's Machinery Orders MoM data set for August 18, 2026, with a forecasted increase of 0.079%, amid positive stock market sentiment and investor confidence in capital spending.

Leer

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK  -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

3

Comprar

2

Mantener

2

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Genmab A-S Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Otras acciones del sector

NOVO.B.DK

Novo Nordisk A-S (Class B)

295.05

↓-1.28%